Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Valeo Pharma Inc T.VPH.DB


Primary Symbol: T.VPH Alternate Symbol(s):  VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler,... see more

Recent & Breaking News (TSX:VPH)

Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program

Canada NewsWire April 28, 2021

Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement

PR Newswire April 27, 2021

Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)

PR Newswire April 15, 2021

Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures

Canada NewsWire April 14, 2021

Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®

PR Newswire April 6, 2021

Valeo Pharma Reports its First Quarter 2021 Results and Highlights

Canada NewsWire March 31, 2021

Acquisition of LSL Laboratory for Nearly $40 Million Dollars - Name Change - Consolidation - Announcement of a Concurrent Private Placement of Maximum $7 Million

GlobeNewswire March 30, 2021

IIROC Trade Resumption - VPH

Canada NewsWire March 29, 2021

Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada

Canada NewsWire March 29, 2021

IIROC Trading Halt - VPH

Canada NewsWire March 26, 2021

Valeo Pharma to Report First Quarter 2021 Results and Hold Investors Conference Call / Webcast

Canada NewsWire March 26, 2021

Valeo Pharma Reports its 2020 Fourth Quarter and Year-End Results and Highlights

Canada NewsWire February 24, 2021

Valeo Pharma to Report Fourth Quarter and 2020 Year-End Results and Hold Investors Conference Call / Webcast

Canada NewsWire February 19, 2021

Valeo Pharma's Hesperco(TM) Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial

PR Newswire February 17, 2021

Valeo Pharma's Redesca(TM) Receives Positive Recommendation for Public Reimbursement in Quebec

Canada NewsWire January 25, 2021

Valeo Pharma Announces Major Addition to its Senior Management Team

Canada NewsWire January 18, 2021

Valeo Pharma Highlights MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

PR Newswire January 12, 2021

Valeo Pharma Announces DTC Eligibility for the Trading of Its Shares on the US OTCQB Market

Canada NewsWire December 29, 2020

Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)

PR Newswire December 9, 2020

Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium

Canada NewsWire November 12, 2020